| Cash Flow | 2026-01-31 | 2025-10-31 | 2025-07-31 |
|---|---|---|---|
| Net loss | -1,985,208 | -2,350,769 | -2,054,994 |
| Depreciation | 6,916 | 7,006 | 7,111 |
| Amortization of debt discounts and deferred financing costs | 21,287 | 263,880 | 109,950 |
| Amortization - right-of-use assets, operating lease | 26,322 | 25,429 | 24,564 |
| Stock-based compensation | 376,100 | 436,884 | 174,558 |
| Warrants issued to non-employees | 78,761 | 29,574 | NaN |
| Accounts receivable | 0 | 0 | -4,350 |
| Inventory | 0 | 7,778 | -760 |
| Prepaid and other current assets | -257,303 | 20,569 | 97,746 |
| Deferred offering costs | 116,707 | 189,674 | 224,900 |
| Capitalized software | 258,420 | 198,703 | NaN |
| Accounts payable | 93,337 | 34,165 | -35,436 |
| Accrued liabilities | 68,179 | -334,208 | 166,718 |
| Lease liability, operating lease | -30,396 | -29,503 | -28,302 |
| Net cash used in operating activities | -1,462,526 | -2,334,266 | -1,953,367 |
| Acquisition of intellectual property - intangibles | 37,344 | 2,740 | 814 |
| Purchase of property and equipment | -9,476 | 13,030 | NaN |
| Net cash used in investing activities | -27,868 | -15,770 | -814 |
| Issuance of series d preferred stock and warrants, net of issuance costs | 5,549,207 | NaN | NaN |
| Issuance of series d prefered stock and warrants, net of issuance costs | NaN | 1,752,831 | 3,796,376 |
| Issuance of common stock, net of fees | 0 | 172,839 | NaN |
| Principal repayments on the 2.5m streeterville note | 450,000 | NaN | NaN |
| Principal repayments on the streeterville note | NaN | 350,000 | 100,000 |
| Proceeds from 3.6m streeterville note, net | 3,000,000 | NaN | NaN |
| Repayments of financed insurance premiums | 63,674 | 66,762 | 48,062 |
| Net cash provided by financing activities | 2,936,326 | 1,508,908 | 3,648,314 |
| Net change in cash and cash equivalents during the period | 1,445,932 | -841,128 | 1,694,133 |
| Cash and cash equivalents at beginning of period | NaN | 1,098,098 | NaN |
| Cash and cash equivalents, beginning of period | 1,951,103 | NaN | NaN |
| Cash and cash equivalents at end of period | NaN | 1,951,103 | NaN |
| Cash and cash equivalents, end of period | 3,397,035 | NaN | NaN |
HeartSciences Inc. (HSCS)
HeartSciences Inc. (HSCS)